DE60109359D1 - Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten - Google Patents

Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten

Info

Publication number
DE60109359D1
DE60109359D1 DE60109359T DE60109359T DE60109359D1 DE 60109359 D1 DE60109359 D1 DE 60109359D1 DE 60109359 T DE60109359 T DE 60109359T DE 60109359 T DE60109359 T DE 60109359T DE 60109359 D1 DE60109359 D1 DE 60109359D1
Authority
DE
Germany
Prior art keywords
ferritine
antibodies
treatment
cancer types
specific cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60109359T
Other languages
English (en)
Other versions
DE60109359T2 (de
Inventor
Jean Kadouche
Rafael Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MONOCLONAL ANTIBODIES THERAPEU
Original Assignee
MONOCLONAL ANTIBODIES THERAPEU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MONOCLONAL ANTIBODIES THERAPEU filed Critical MONOCLONAL ANTIBODIES THERAPEU
Application granted granted Critical
Publication of DE60109359D1 publication Critical patent/DE60109359D1/de
Publication of DE60109359T2 publication Critical patent/DE60109359T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60109359T 2000-01-20 2001-01-19 Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten Expired - Lifetime DE60109359T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0000718A FR2804027B1 (fr) 2000-01-20 2000-01-20 Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
FR0000718 2000-01-20
PCT/FR2001/000192 WO2001052889A1 (fr) 2000-01-20 2001-01-19 Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers

Publications (2)

Publication Number Publication Date
DE60109359D1 true DE60109359D1 (de) 2005-04-21
DE60109359T2 DE60109359T2 (de) 2006-04-13

Family

ID=8846119

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60109359T Expired - Lifetime DE60109359T2 (de) 2000-01-20 2001-01-19 Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten

Country Status (10)

Country Link
US (2) US7153506B2 (de)
EP (1) EP1165134B1 (de)
JP (1) JP2003520250A (de)
AT (1) ATE290881T1 (de)
AU (1) AU3556901A (de)
CA (1) CA2387383C (de)
DE (1) DE60109359T2 (de)
ES (1) ES2239126T3 (de)
FR (1) FR2804027B1 (de)
WO (1) WO2001052889A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412890B8 (pt) 2003-07-24 2021-05-25 Innate Pharma método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
EP1563851A1 (de) * 2004-02-17 2005-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Verbindung eines Antikörpers mit einer kationischen Emulsion als Drogenlieferungs-System
CA2575607C (en) 2004-08-03 2017-07-11 Innate Pharma Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
GB0420566D0 (en) * 2004-09-16 2004-10-20 Sec Dep For Environment Food & Assay method
WO2007034479A2 (en) * 2005-09-20 2007-03-29 Yissum Research Development Company Nanoparticles for targeted delivery of active agents
GB0612825D0 (en) * 2006-06-28 2006-08-09 Iti Scotland Ltd Analyte detection
GB0616508D0 (en) * 2006-08-18 2006-09-27 Iti Scotland Ltd Analyte manipulation and detection
US20090053736A1 (en) * 2007-08-21 2009-02-26 Mattingly Phillip G Homogeneous Chemiluminescent Immunoassay for Analysis of Iron Metalloproteins
CA2696634A1 (en) * 2007-09-19 2009-03-26 Monoclonal Antibodies Therapeutics Monoclonal antibodies against human acidic and basic ferritins and nucleotide and amino acid sequences thereof
US8728477B2 (en) 2007-09-19 2014-05-20 Immune Pharmaceuticals Ltd. Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5843440A (en) * 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
EP0627941A1 (de) * 1992-02-28 1994-12-14 ORDER, Stanley E. VERWENDUNG VON AGGREGIERTEN PROTEINEN ZUR VERLäNGERUNG DER VERWEILDAUER EINES WIRKSTOFFES AM ZIELORT; WIE ZUM BEISPIEL BEI EINEM TUMOR

Also Published As

Publication number Publication date
DE60109359T2 (de) 2006-04-13
EP1165134A1 (de) 2002-01-02
CA2387383A1 (fr) 2001-07-26
ATE290881T1 (de) 2005-04-15
FR2804027A1 (fr) 2001-07-27
US7153506B2 (en) 2006-12-26
EP1165134B1 (de) 2005-03-16
CA2387383C (fr) 2008-10-21
AU3556901A (en) 2001-07-31
JP2003520250A (ja) 2003-07-02
WO2001052889A1 (fr) 2001-07-26
FR2804027B1 (fr) 2002-08-30
ES2239126T3 (es) 2005-09-16
US20070042447A1 (en) 2007-02-22
US20020106324A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
CY1107453T1 (el) Baff, σχετικοι δεσμευτικοι παραγοντες και χρηση αυτων στη διεγερση και αναστολη β-κυτταρων και ανοσοσφαιρινων σε ανοσοαποκρισεις
DE69433406T2 (de) Antikörper gegen cd40
BR0011838A (pt) Elementos misturadores estáticos empilhados
ATE177754T1 (de) Fragmente von prion proteinen.
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
PT1572087E (pt) Anticorpos contra o antigénio de cancro tmeff2 e suas utilizações
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
GB9924957D0 (en) Novel treatment
ES2098274T3 (es) Anticuerpos monoclonales.
DE69622259T2 (de) Cd40 bindendes protein zur stimulierung der immunantwort
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
DE69615843T2 (de) Il-8 antagonisten zur behandlung von asthma
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
GB0004576D0 (en) Proteins
DE602005025459D1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition